FDA approves Avtozma (tocilizumab-anoh) in both an intravenous and subcutaneous formulation as a biosimilar to Actemra – Celltrion
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
